FDA Clears Roche and C2N Alzheimer’s Blood Tests, Expanding Earlier Amyloid Detection

FDA Adds Two Alzheimer’s Blood Tests to the Diagnostic Toolbox

The U.S. Food and Drug Administration has cleared two new blood tests designed to help clinicians assess whether a person with cognitive symptoms has amyloid pathology, a hallmark of Alzheimer’s disease. Roche’s Elecsys pTau217, developed with Eli Lilly, and C2N Diagnostics’ PrecivityAD2 bring the number of FDA-cleared Alzheimer’s blood tests to four. PrecivityAD2 is the first such test indicated for symptomatic adults as young as 40; Roche’s test is for adults 55 and older with signs, symptoms or complaints of cognitive decline.

Neither test is intended to diagnose Alzheimer’s disease on its own. Elecsys pTau217 measures a single blood biomarker, phosphorylated tau 217, and returns positive, intermediate or negative results. PrecivityAD2 combines an amyloid-beta 42/40 ratio with a p-tau217/np-tau217 ratio. In a validation study of 1,142 people with cognitive symptoms, PrecivityAD2 had a positive predictive value of 97.6% and a negative predictive value of 93.1% against amyloid PET scans or cerebrospinal fluid biomarkers. Roche reported that Elecsys pTau217 agreed with amyloid PET results in about 88% of people with cognitive impairment and 91% of people without cognitive impairment in a study of more than 2,100 adults. C2N says the FDA-cleared version is expected later in 2026.

The practical appeal is that blood testing is less invasive and potentially more accessible than PET imaging or lumbar puncture. But the FDA and the manufacturers stress that results must be interpreted with symptoms, medical history and other clinical findings. Dr. Dung Trinh, an internist not involved with either test, said blood biomarkers could help some symptomatic younger adults get an explanation earlier, but they are not meant for routine screening of healthy people in their 40s.

What Roche’s Elecsys pTau217 and C2N’s PrecivityAD2 Change About Diagnosis

Roche’s cobas network gives it a primary-care distribution advantage

The Elecsys pTau217 test is designed to run on Roche’s existing cobas laboratory instruments, and the company says more than 4,500 of those systems are already installed in U.S. laboratories. That installed base lowers the practical barrier to adoption: laboratories and health systems can add the test without building new testing capacity. If clinicians use it in primary care as well as specialist settings, it could shift biomarker assessment earlier in the diagnostic pathway, which is where many patients first raise cognitive concerns.

C2N’s 40-and-older label is a first, but the evidence base is thinner

PrecivityAD2’s indication for symptomatic adults ages 40 and older gives C2N a differentiating claim, but it is not a screening approval. Dr. Trinh cautioned that Alzheimer-related amyloid pathology is less common at younger ages, so the pre-test probability is lower and interpretation depends heavily on the broader clinical picture. He also noted that very young patients were relatively few in validation studies, meaning the overall 97.6% positive predictive value may not apply identically to adults in their 40s. Positive results in younger patients can have profound work, family, financial and emotional consequences, making patient selection and counselling essential.

Blood tests are being positioned as a gateway, not a final verdict

The clearest clinical role for both tests is triage: identify people in whom amyloid pathology is unlikely, flag those who need specialist evaluation, and reduce unnecessary PET or CSF testing for clear negatives. Roche explicitly frames Elecsys pTau217 as a way to help clinicians decide whether additional evaluation or referral is appropriate. The unresolved questions are real: how intermediate results should be managed, how reimbursement will work, and when confirmatory imaging remains necessary. With the earlier Lumipulse test already cleared, the market is becoming more competitive, but the evidence and distribution advantages are uneven.

What Patients, Clinicians, and Diagnostic Makers Should Do Next

The clearances create different practical steps for the people most directly affected.

• Patients with cognitive symptoms: Ask a physician whether amyloid blood testing fits your clinical evaluation. A clearly negative result can make amyloid pathology less likely and shift attention to other causes; a positive or intermediate result still requires clinical workup and, often, specialist assessment.
• Adults in their 40s: Do not treat PrecivityAD2 as a screening check. Its 40-and-older indication applies only when you already have signs or symptoms of cognitive impairment and are being evaluated; sleep, mood, metabolic and neurologic causes should also be considered.
• Primary care practices: If you use Elecsys pTau217, use its positive, negative and intermediate categories to guide referral decisions, but build a clear follow-up path for intermediate results rather than treating the test as a diagnosis.
• Roche and Eli Lilly: The installed cobas base of more than 4,500 U.S. laboratories is the commercial asset to leverage, but clinician education must emphasize that the test is a gateway in the diagnostic pathway, not a standalone diagnosis.
• C2N Diagnostics: The FDA-cleared PrecivityAD2 version is expected later in 2026; generating more validation data in adults in their 40s will be critical to defending the first-in-class younger indication.